Not all patients with CLL demand therapy. Even with all the latest improvements, the iwCLL even now recommends watchful observation for sufferers with asymptomatic condition.86 This advice relies on at the very least two randomized trials evaluating observation to both chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).10